An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...
After decades of stagnation in the drug treatment of schizophrenia, a handful of new therapies have raised hopes of improvement – but one of them has just failed a pair of phase 3 trials. Sumitomo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results